All News

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

The novel rapid-acting psychedelic agent produced antidepressant effects within 24 hours after the first infusion, with a -18.5 point change in MADRS from baseline.

Telemedicine's trajectory depends far more on future regulatory action than on health care's readiness or patient desire, according to a new report.

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Your daily dose of the clinical news you may have missed.

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Your daily dose of the clinical news you may have missed.

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.

Itch relief in clinical trials was rapid with the nonsteroidal foam; it is applied once daily with no limitations on body area or duration of use.